Lipocine Meets Resolution Regulatory Endpoint In Mid-Stage NASH Trial

Lipocine Inc LPCN has announced topline 36-week results from its Phase 2 proof of concept LiFT study investigating LPCN 1144 in Non-Alcoholic Steatohepatitis (NASH).

  • LPCN 1144 comprises an orally delivered prodrug of endogenous testosterone (T).
  • At 12 weeks Statistically significant reduction in liver fat was observed compared to placebo (primary endpoint): up to a mean of 9.2% absolute reduction and a 46.8% relative reduction in liver fat. 
  • Related: Lipocine To Start Testing Neuro-Steroid Candidate In Postpartum Depression Patients
  • Both LPCN 1144 treatment arms met with statistical significance the pre-specified accelerated approval regulatory endpoint of NASH resolution with no worsening of fibrosis based on NASH CRN scoring. 
  • Additionally, both treatment arms showed substantial improvement of the observed NASH activity in steatosis, inflammation, and ballooning.
  • In both treatment arms, substantial and sustained reductions in markers of liver injury compared to placebo were observed.
  • During the 36 weeks of treatment, LPCN 1144 was well tolerated with an overall safety profile comparable to placebo. 
  • Price Action: LPCN shares are up 1.43% at $1.23 during the premarket session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechLong IdeasNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefsNASHNon Alcoholic steatohepatitisPhase 2 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!